Clinical Trial with Clofazimine for Treating Erythema Dyschromicum Perstans Evaluation of Cell‐Mediated Immunity

Abstract

Eight patients were studied to determine the possible use of clofazimine for treating erythema dyschromicum perstans (EDP). The T-helper/T-suppressor cytotoxic ratio (CD-4/CD-8) and the in vitro lymphoproliferative response on stimulation with phytohemaglutin (PHA) and concanavalin A (Con A) were determined in peripheral blood before and after treatment. Of the eight patients studied, seven had excellent to good responses, whereas only one had a marginal response. The immunologic evaluation before and after treatment showed a significant change in the CD-4/CD-8 ratio, a decrease of the response to PHA, and no change in the response to Con A. The results obtained show that clofazimine is useful for treating this nosologic entity because of its cosmetic effect, and also because it induces changes in cell-mediated response, which could be very important therapeutically.

Erythema Dyschromicum Perstans in Prepubertal Children

“…Excluding those for whom follow‐up or clinical course was unavailable, the condition resolved or improved significantly in 69% of prepubertal patients and in all of our patients with a documented course. It should be noted that one of these patients showed clearance after receiving clofazimine (5). However, none of the other patients had been administered therapy at the time of resolution or improvement.…”

Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study

“…To date, no effective standard treatment is available, although some good results with clofazimine and dapsone have been reported in small case series (2)(3)(4)(5). Histopathology shows vacuolar degeneration of the basal cells and pigment incontinence with many melanophages in the upper dermis of active lesions (6).…”

Ashy dermatosis: A comprehensive review

“…The patients were given tablet clofazimine 100mg daily for 3 months [31,32]. The response rates varied from 66% to 87%.…”